低污染抗微生物疫苗
By controlling the number of oligosaccharide-(16)-glucosamine groups and using staged filtration, the problems of toxoid oligomerization and amino contaminants in the vaccine composition were solved, achieving effective immunity and vaccine stability against microorganisms with polymerized N-acetyl-(16)-glucosamine groups.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ALOPEXX INC
- Filing Date
- 2020-11-11
- Publication Date
- 2026-07-17
AI Technical Summary
Existing vaccine compositions suffer from problems such as toxoid oligomerization and amino contaminants, which lead to complex and heterogeneous vaccine purification and affect immunization efficacy.
By controlling the number of oligosaccharide-(16)-glucosamine groups in the vaccine composition and the purification process, the ratio of monomers and dimer toxoids in the composition is ensured to be appropriate, and oligomers and amino contaminants are removed by staged filtration to form a stable vaccine composition.
Effective immunity against microorganisms containing polymeric N-acetyl-(16)-glucosamine groups was achieved, reducing the impact of impurities and improving the stability of the vaccine and the uniformity of the immune response.
Smart Images
Figure CN122399008A_ABST